Kristi Rosa

Joshua M. Bauml, MD, discusses challenges in providing care to patients with lung cancer in light of the COVID-19 pandemic and ongoing efforts to reduce unnecessary exposure to the virus.

Experts from The Ohio State University Comprehensive Cancer Center–The James as well as Blanchard Valley Health System discussed the impact of the COVID-19 pandemic on cancer care.

An expert panel of oncologists addresses the oncology community’s response to the COVID-19 crisis.

Experts from Mayo Clinic, Ironwood Cancer and Research Centers, and Banner MD Anderson Cancer Center Clinic discuss the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

As the number of confirmed cases of COVID-19 continues to grow, oncologists from all over the world are working together to stay informed on the latest developments, participate in pivotal research efforts, develop potentially life-saving medications, and share personal experiences faced in practice to ultimately improve patient care.

Omid Hamid, MD, discusses ongoing efforts to quell the COVID-19 pandemic, the benefits of telemedicine, and promising research being done to combat the virus.

Balazs Halmos, MD, MA, discusses the advances that have been made in the treatment of patients with metastatic non–small cell lung cancer, ongoing biomarker research, and the importance of molecular testing.

As the novel coronavirus continues its rapid global spread, many oncology-based organizations have been forced to make the difficult decision to either cancel or postpone highly anticipated medical conferences.

Balazs Halmos, MD, discusses the implications of the emergence of osimertinib in the frontline treatment of patients with EGFR-mutated non–small cell lung cancer, the efforts being made to address resistance to the third-generation EGFR TKI, and the promise of circulating tumor DNA in the space.

Key opinion leaders in the field share what they considered to be the greatest takeaways from the 2020 Genitourinary Cancers Symposium and provide insight on where treatment is headed in their respective areas of expertise.

In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.

The first-in-class nucleotide analogue NUC-1031 has demonstrated early clinical activity in heavily pretreated patients with platinum-resistant ovarian cancer.

As coronavirus disease 2019 (COVID-19) continues to spread around the world, several oncology-based organizations are taking precautionary measures to protect physicians and patients alike from infection, including making the decision to postpone, or even cancel, select medical conferences.

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

Experts from Memorial Sloan Kettering Cancer Center and NYU Langone Health’s Perlmutter Cancer Center highlight some of the exciting research efforts being conducted at their respective institutions.

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend polatuzumab vedotin plus rituximab and bendamustine for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma who cannot undergo hematopoietic stem cell transplant.

Experts from Virginia Cancer Specialists, Georgetown University, Dana-Farber Cancer Institute, and Johns Hopkins Medicine to provide insight on some of the pivotal research being conducted at their respective institutions.

R. Lor Randall, MD, FACS, highlights the specific challenges faced by adolescent and young adult patients with sarcomas, the importance of promoting awareness of this issue, and the resources available to improve outcomes in this population.

Neeraj Agarwal, MD, discusses the COSMIC-021 trial and shares the next steps for this research.

Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.

Yelena Janjigian, MD, highlights key updates from the 2020 Gastrointestinal Cancers Symposium and explained the impact that new data will have on clinical practice.

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend the combination of pembrolizumab and axitinib for use in treatment-naïve adult patients with advanced renal cell carcinoma.

Faculty from NewYork-Presbyterian Hospital/Columbia University Irving Medical Center share their resolutions for the new year and the efforts being made to improve patient outcomes in practice.

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Kevin Kalinsky, MD, MS, highlights recent developments in triple-negative breast cancer, including the potential role of immunotherapy in the neoadjuvant setting.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection for use in combination with erlotinib in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.

The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.

Three biosimilars—bevacizumab-bvzr (Zirabev), rituximab-pvvr (Ruxience), and trastuzumab-qyyp)—will become available in the United States at a substantial discount to their reference products.